查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822370

2032 年敗血症治療抗生素市場預測：依藥物類別、病原體類型、給藥途徑、通路、應用、最終用戶和地區進行分析

Septicemia Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Pathogen Type, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球用於治療敗血症的抗生素市場預計在 2025 年達到 27.3 億美元，到 2032 年將達到 38.2 億美元，預測期內的複合年成長率為 4.9%。

用於治療敗血症的抗生素是控制血液細菌感染的重要處方藥。敗血症，通常被稱為血液中毒，如果不緊急治療，可能會迅速致命。這些抗生素透過破壞或抑制細菌生長發揮作用，有助於預防器官損傷和全身併發症。根據感染源的不同，治療方案包括頻譜或特異性病原體的抗生素，以確保有效控制病情。使用這些抗生素對於降低與敗血症相關的死亡率至關重要。

根據發表在《Science Direct》雜誌上的一項研究，2025年6月，1,085名住院患者中，16.7%患有細菌感染疾病。

血液感染疾病增加

醫院接診的敗血症患者數量激增，這些敗血症患者與慢性疾病、侵入性操作以及導管相關感染有關。隨著診斷工具日益複雜，早期發現血液中的病原體有助於改善臨床療效。快速分子診斷與基於人工智慧的感染追蹤技術的結合正在改變治療通訊協定。新興國家正在投資微生物實驗室和監測系統，以遏制醫院內感染。日益加重的負擔正在推動廣譜抗生素和特異性病原體的抗生素的創新。

難以取得有效的抗生素

監管障礙和高昂的研發成本阻礙了製藥公司開發新型抗生素。許多現有抗生素由於過度使用（尤其是在加護治療環境中）以及微生物適應性而失效。開發符合全球安全標準並針對多重抗藥性細菌的藥物的複雜性加劇了這項挑戰。規模較小的生物技術公司難以資金籌措臨床試驗並順利通過核准途徑。如果沒有加速創新和全球管理計劃，我們的抗生素庫存仍然非常有限。

提高早期診斷意識

人們越來越意識到敗血症早期診斷的重要性，這為市場拓展開闢了新的途徑。醫院正在採用就地檢驗和基於生物標記的篩檢，以便及時啟動抗生素治療。基因組定序和人工智慧診斷平台的進步使得快速識別血液中的病原體成為可能。公共衛生宣傳活動和臨床醫生培訓計畫正在強化早期療育的價值。政府和非政府組織正在為醫療資源匱乏的地區提供診斷基礎設施資金，以降低死亡率。向主動護理的轉變正在推動對伴隨診斷和客製化抗生素治療方案的需求。

抗藥性患者治療失敗的風險

抗藥性患者的治療失敗往往會導致住院時間延長、死亡率上升和醫療費用上升。儘管聯合治療和最後一線抗生素取得了進展，但抗藥性機制仍在不斷演變。醫院已經實施了抗生素管理計劃和抗藥性監測工具，但不同地區的實施情況存在差異。由於缺乏全抗藥性感染疾病的有效替代方案，迫切需要全球合作進行藥物研發。如果沒有強力的遏制策略，抗藥性敗血症可能會阻礙治療進展。

COVID-19的影響

COVID-19疫情擾亂了抗生素供應鏈，改變了臨床治療重點，並延誤了常規敗血症的診斷和治療。由於醫院關閉和生產瓶頸，醫院面臨關鍵抗生素和診斷劑的短缺。然而，這場危機加速了遠端醫療和遠端監控在感染控制的應用。疫情後的策略如今強調分散式照護、抗菌藥物管理和人工智慧驅動的感染監測。疫情也凸顯了建立韌性供應鏈和多元化抗生素採購的重要性。

頭孢菌素類藥物預計將成為預測期內最大的藥物

頭孢菌素類抗生素因其頻譜療效和良好的安全性，預計在預測期內將佔據最大的市場佔有率。這些抗生素廣泛用於血流感染疾病的經驗性治療，尤其是在醫院。第三代和第四代頭孢菌素的技術進步提高了抗藥性覆蓋率和藥物動力學。醫院在等待病原體特異性診斷期間，越來越依賴頭孢菌素作為初始治療。新興趨勢包括複方製劑和緩釋性，以提高依從性。持續的技術創新和臨床偏好正在鞏固頭孢菌素在抗生素市場的領先地位。

預測期內，敗血性休克領域預計將實現最高複合年成長率

預計在預測期內，敗血性休克領域將出現最高成長率，這得益於重症監護病房 (ICU) 入院人數和重症患者介入措施的增加。敗血性休克病例需要快速有效的抗生素治療以及血流動力學支持，因此成為治療創新的重點。醫院正在採用即時監控系統和基於人工智慧的決策支援來管理這些高風險患者。針對產生內毒素的病原體的下一代抗生素的開發正在蓬勃發展。臨床試驗正在探索免疫調節藥物和精準給藥演算法等輔助性治療。人們對敗血性休克死亡率的認知不斷提高，這加速了對針對性解決方案的投資。

比最大的地區

受醫療基礎設施擴張和感染率上升的推動，亞太地區預計將在預測期內佔據最大的市場佔有率。印度、中國和印尼等國家正在投資醫院升級和抗菌藥物管理計畫。政府舉措正在促進國內抗生素生產，並改善診斷的可及性。該地區正在迅速普及數位健康平台和人工智慧驅動的感染監測。全球製藥公司與本地製造商之間的策略聯盟正在加強市場滲透。

複合年成長率最高的地區：

在強勁的研發投入和先進的醫療體系的推動下，北美預計將在預測期內呈現最高的複合年成長率。美國和加拿大在新型抗生素和快速診斷技術的開發方面處於領先地位。監管機構正在簡化針對抗藥性敗血症菌株的突破性治療方法的核准流程。醫院正在整合物聯網驅動的監測和預測分析，以最佳化抗生素的使用。該地區受益於健全的報銷框架和精準醫療的高度普及。隨著抗生素抗藥性成為國家優先事項，北美將繼續推動創新和市場成長。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球敗血症抗生素市場（依藥物類別）

  • 頭孢菌素類
  • 卡巴培南類
  • 糖肽
  • 青黴素
  • Aminoglycosides
  • 其他藥物類別

6. 全球敗血症抗生素市場（依病原體類型）

  • 細菌
    • 革蘭氏陽性
    • 革蘭氏陰性
  • 病毒性的
  • 真菌

7. 全球敗血症治療用抗生素市場（依給藥途徑）

  • 腸外
  • 口服

8. 全球敗血症治療抗生素市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

9. 全球敗血症治療抗生素市場（依應用）

  • 敗血症
  • 敗血性休克
  • 嚴重敗血症
  • 其他用途

第 10 章。全球敗血症治療抗生素市場（按最終用戶）

  • 醫院及重症監護室
  • 診斷實驗室
  • 專科診所
  • 其他最終用戶

11. 全球敗血症治療抗生素市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • Pfizer Inc.
  • Endacea Inc.
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • GlaxoSmithKline plc（GSK）
  • RegeneRx Biopharmaceuticals Inc.
  • AbbVie Inc.
  • Novartis AG
  • Viatris Inc.
  • AstraZeneca plc
  • Asahi Kasei Corporation
  • Eli Lilly and Company
  • Adrenomed AG
  • Merck & Co., Inc.
  • Inotrem SA
Product Code: SMRC31124

According to Stratistics MRC, the Global Septicemia Antibiotics Market is accounted for $2.73 billion in 2025 and is expected to reach $3.82 billion by 2032 growing at a CAGR of 4.9% during the forecast period. Antibiotics for septicemia are vital drugs prescribed to manage bacterial infections in the bloodstream. Commonly referred to as blood poisoning, septicemia can rapidly become fatal without urgent treatment. These antibiotics act by destroying or inhibiting bacterial growth, helping prevent organ damage and systemic complications. Depending on the infection source, therapy may involve broad-spectrum or pathogen-specific antibiotics, ensuring effective control of the disease. Their use is essential in lowering death rates linked with septicemia.

According to the study published by Science Direct, in June 2025, out of 1,085 hospitalized patients, 16.7% had bacterial infection.

Market Dynamics:

Driver:

Rising prevalence of bloodstream infections

Hospitals are witnessing a surge in septicemia cases linked to chronic illnesses, invasive procedures, and catheter-related infections. As diagnostic tools become more sophisticated, early detection of bloodstream pathogens is improving clinical outcomes. The integration of rapid molecular diagnostics and AI-based infection tracking is transforming treatment protocols. Emerging economies are investing in microbiology labs and surveillance systems to curb hospital-acquired infections. This growing burden is driving innovation in broad-spectrum and pathogen-specific antibiotic formulations.

Restraint:

Limited availability of effective antibiotics

Regulatory hurdles and high R&D costs are discouraging pharmaceutical firms from pursuing new antimicrobial agents. Many existing antibiotics are losing efficacy due to overuse and microbial adaptation, especially in intensive care settings. The complexity of developing drugs that meet global safety standards while targeting multi-drug resistant organisms adds to the challenge. Smaller biotech firms struggle with clinical trial funding and navigating approval pathways. Without accelerated innovation and global stewardship programs, the antibiotic arsenal remains dangerously limited.

Opportunity:

Increasing awareness of early diagnosis

Heightened awareness around the importance of early diagnosis in septicemia is opening new avenues for market expansion. Hospitals are adopting point-of-care testing and biomarker-based screening to initiate timely antibiotic therapy. Advances in genomic sequencing and AI-powered diagnostic platforms are enabling faster identification of bloodstream pathogens. Public health campaigns and clinician training programs are reinforcing the value of early intervention. Governments and NGOs are funding diagnostic infrastructure in underserved regions to reduce mortality rates. This shift toward proactive care is boosting demand for companion diagnostics and tailored antibiotic regimens.

Threat:

Risk of treatment failure in resistant cases

Treatment failure in resistant cases often leads to prolonged hospitalization, increased mortality, and higher healthcare costs. Despite advances in combination therapies and last-resort antibiotics, resistance mechanisms continue to evolve. Hospitals are deploying antimicrobial stewardship programs and resistance monitoring tools, but adoption remains uneven across regions. The lack of effective alternatives for pan-resistant infections is prompting urgent calls for global collaboration in drug development. Without robust containment strategies, resistant septicemia could undermine therapeutic progress.

Covid-19 Impact

The COVID-19 pandemic disrupted antibiotic supply chains and shifted clinical priorities, delaying routine septicemia diagnosis and treatment. Hospitals faced shortages of critical antibiotics and diagnostic reagents due to lockdowns and manufacturing bottlenecks. However, the crisis accelerated adoption of telemedicine and remote monitoring for infection management. \ Post-pandemic strategies now emphasize decentralized care, antimicrobial stewardship, and AI-driven infection surveillance. The pandemic also highlighted the need for resilient supply chains and diversified antibiotic sourcing.

The cephalosporins segment is expected to be the largest during the forecast period

The cephalosporins segment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and favorable safety profile. These antibiotics are widely used in empirical therapy for bloodstream infections, especially in hospital settings. Technological advancements in third- and fourth-generation cephalosporins are enhancing resistance coverage and pharmacokinetics. Hospitals are increasingly relying on cephalosporins for initial treatment while awaiting pathogen-specific diagnostics. Emerging trends include fixed-dose combinations and extended-release formulations to improve compliance. Continuous innovation and clinical preference are reinforcing cephalosporins' leadership in the antibiotic landscape.

The septic shock segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the septic shock segment is predicted to witness the highest growth rate, driven by rising ICU admissions and critical care interventions. Septic shock cases demand rapid, potent antibiotic administration alongside hemodynamic support, making them a priority for therapeutic innovation. Hospitals are adopting real-time monitoring systems and AI-based decision support to manage these high-risk patients. The development of next-gen antibiotics targeting endotoxin-producing pathogens is gaining momentum. Clinical trials are exploring adjunct therapies like immunomodulators and precision dosing algorithms. As awareness of septic shock mortality grows, investment in targeted solutions is accelerating.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by expanding healthcare infrastructure and rising infection rates. Countries like India, China, and Indonesia are investing in hospital upgrades and antimicrobial stewardship programs. Government initiatives are promoting domestic antibiotic production and improving access to diagnostics. The region is witnessing rapid adoption of digital health platforms and AI-driven infection surveillance. Strategic collaborations between global pharma firms and local manufacturers are enhancing market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by strong R&D investment and advanced healthcare systems. The U.S. and Canada are leading in the development of novel antibiotics and rapid diagnostic technologies. Regulatory agencies are streamlining approval processes for breakthrough therapies targeting resistant septicemia strains. Hospitals are integrating IoT-enabled monitoring and predictive analytics to optimize antibiotic use. The region benefits from robust reimbursement frameworks and high adoption of precision medicine. As antimicrobial resistance becomes a national priority, North America continues to drive innovation and market growth.

Key players in the market

Some of the key players profiled in the Septicemia Antibiotics Market include Pfizer Inc., Endacea Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline plc (GSK), RegeneRx Biopharmaceuticals Inc., AbbVie Inc., Novartis AG, Viatris Inc., AstraZeneca plc, Asahi Kasei Corporation, Eli Lilly and Company, Adrenomed AG, Merck & Co., Inc., and Inotrem S.A.

Key Developments:

In September 2025, Johnson & Johnson announced the European launch of its Shockwave Javelin Peripheral IVL Catheter, a novel intravascular lithotripsy (IVL) platform designed to modify calcium in extremely narrowed vessels to expand treatments in patients suffering from peripheral artery disease (PAD).

In July 2025, Pfizer Inc. announced the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio's SSGJ-707, a bispecific antibody targeting PD-1 and VEGF developed using 3SBio's proprietary CLF2 platform. This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company's robust oncology pipeline.

Drug Classes Covered:

  • Cephalosporins
  • Carbapenems
  • Glycopeptides
  • Penicillins
  • Aminoglycosides
  • Other Drug Classes

Pathogen Types Covered:

  • Bacterial
  • Viral
  • Fungal

Route of Administrations Covered:

  • Parenteral
  • Oral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Sepsis
  • Septic Shock
  • Severe Sepsis
  • Other Applications

End Users Covered:

  • Hospitals & ICUs
  • Diagnostic Laboratories
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Septicemia Antibiotics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Cephalosporins
  • 5.3 Carbapenems
  • 5.4 Glycopeptides
  • 5.5 Penicillins
  • 5.6 Aminoglycosides
  • 5.7 Other Drug Classes

6 Global Septicemia Antibiotics Market, By Pathogen Type

  • 6.1 Introduction
  • 6.2 Bacterial
    • 6.2.1 Gram-positive
    • 6.2.2 Gram-negative
  • 6.3 Viral
  • 6.4 Fungal

7 Global Septicemia Antibiotics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Septicemia Antibiotics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Online Pharmacies
  • 8.4 Retail Pharmacies

9 Global Septicemia Antibiotics Market, By Application

  • 9.1 Introduction
  • 9.2 Sepsis
  • 9.3 Septic Shock
  • 9.4 Severe Sepsis
  • 9.5 Other Applications

10 Global Septicemia Antibiotics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & ICUs
  • 10.3 Diagnostic Laboratories
  • 10.4 Specialty Clinics
  • 10.5 Other End Users

11 Global Septicemia Antibiotics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Endacea Inc.
  • 13.3 F. Hoffmann-La Roche Ltd
  • 13.4 Johnson & Johnson
  • 13.5 GlaxoSmithKline plc (GSK)
  • 13.6 RegeneRx Biopharmaceuticals Inc.
  • 13.7 AbbVie Inc.
  • 13.8 Novartis AG
  • 13.9 Viatris Inc.
  • 13.10 AstraZeneca plc
  • 13.11 Asahi Kasei Corporation
  • 13.12 Eli Lilly and Company
  • 13.13 Adrenomed AG
  • 13.14 Merck & Co., Inc.
  • 13.15 Inotrem S.A.

List of Tables

  • Table 1 Global Septicemia Antibiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Septicemia Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Septicemia Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
  • Table 4 Global Septicemia Antibiotics Market Outlook, By Carbapenems (2024-2032) ($MN)
  • Table 5 Global Septicemia Antibiotics Market Outlook, By Glycopeptides (2024-2032) ($MN)
  • Table 6 Global Septicemia Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
  • Table 7 Global Septicemia Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
  • Table 8 Global Septicemia Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 9 Global Septicemia Antibiotics Market Outlook, By Pathogen Type (2024-2032) ($MN)
  • Table 10 Global Septicemia Antibiotics Market Outlook, By Bacterial (2024-2032) ($MN)
  • Table 11 Global Septicemia Antibiotics Market Outlook, By Gram-positive (2024-2032) ($MN)
  • Table 12 Global Septicemia Antibiotics Market Outlook, By Gram-negative (2024-2032) ($MN)
  • Table 13 Global Septicemia Antibiotics Market Outlook, By Viral (2024-2032) ($MN)
  • Table 14 Global Septicemia Antibiotics Market Outlook, By Fungal (2024-2032) ($MN)
  • Table 15 Global Septicemia Antibiotics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 16 Global Septicemia Antibiotics Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 17 Global Septicemia Antibiotics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 18 Global Septicemia Antibiotics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 19 Global Septicemia Antibiotics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 20 Global Septicemia Antibiotics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 21 Global Septicemia Antibiotics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 22 Global Septicemia Antibiotics Market Outlook, By Application (2024-2032) ($MN)
  • Table 23 Global Septicemia Antibiotics Market Outlook, By Sepsis (2024-2032) ($MN)
  • Table 24 Global Septicemia Antibiotics Market Outlook, By Septic Shock (2024-2032) ($MN)
  • Table 25 Global Septicemia Antibiotics Market Outlook, By Severe Sepsis (2024-2032) ($MN)
  • Table 26 Global Septicemia Antibiotics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 27 Global Septicemia Antibiotics Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Septicemia Antibiotics Market Outlook, By Hospitals & ICUs (2024-2032) ($MN)
  • Table 29 Global Septicemia Antibiotics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 30 Global Septicemia Antibiotics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 31 Global Septicemia Antibiotics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.